Thyroid News

WASHINGTON — In this video exclusive, Stephanie Lee, MD, professor of medicine and director of the Thyroid Health Center, section of endocrinology, diabetes and nutrition at Boston Medical Center, and Endocrine Today Editorial Board Member, discusses research aimed at creating a more up-to-date and demographically diverse thyroid cancer registry.

BLU-667, an investigational once-daily oral RET inhibitor, induced durable responses among patients with advanced RET-altered medullary thyroid cancer or papillary thyroid cancer, according to data presented at the Annual Meeting of the American Thyroid Association.

WASHINGTON — In this video exclusive, Maria Papaleontiou, MD, assistant professor of internal medicine in the division of metabolism, endocrinology and diabetes at the University of Michigan, discusses the substantial impact worry about thyroid cancer recurrence and death exerts on quality of life for years following treatment.

LOXO-292 appeared effective among heavily pretreated patients with RET-mutant medullary thyroid cancer or RET fusion-positive thyroid cancer, according to data presented at the Annual Meeting of the American Thyroid Association.

WASHINGTON — In this video exclusive, Stephanie L. Lee, MD, PhD, professor of medicine and director of the Thyroid Health Center, section of endocrinology, diabetes and nutrition at Boston Medical Center, and Endocrine Today Editorial Board Member, affiliation, discusses research on thyroid nodules presented at the Annual Meeting of the American Thyroid Association. She also offers her predictions for future breakthroughs.

WASHINGTON — Patients who have undergone thyroidectomy can be safely discharged on the same day when an institution-specific protocol, adapted from the American Thyroid Association Statement on Outpatient Thyroidectomy, is applied, according to data presented at the 88th Annual Meeting of the American Thyroid Association.

WASHINGTON — The development of a comprehensive thyroid cancer registry in urban hospitals with racially, ethnically and socioeconomically diverse patients may aid in understanding risk factors for tumor persistence and recurrence in underserved populations, according to data presented at the 88th Annual Meeting of the American Thyroid Association.

Adults with subclinical hypothyroidism assigned to levothyroxine therapy for at least 3 months experienced no improvements in general quality of life or thyroid-related symptoms vs. similar patients assigned to placebo or no treatment, according to findings from a meta-analysis published in JAMA.

Oncocytic variant papillary thyroid cancer was not shown to confer a higher risk for recurrence when compared with classical papillary thyroid cancer in a retrospective medical record review published in Thyroid.

Adults with subclinical hypothyroidism are at increased risk for cardiovascular disease and all-cause mortality, and the link is amplified for those already predisposed to CVD, including those with diabetes, according to findings published in Thyroid.